

# europaean journal of gynaecological oncology

an International Journal

*Editors-in-Chief*

**A. Onnis** **P. Bószé**  
*Montréal (Canada) Budapest (Hungary)*

*Associate Editor*

**M. Marchetti**  
*Montréal (Canada)*

*Assistant Editor*

**J. Wilson**  
*San Diego - CA (USA)*

*Editorial Board*

Allen H.H., <i>London, Ontario (Canada)</i>	Geisler H.E., <i>Indianapolis, IN (USA)</i>	Menczer J., <i>Savyon (Israel)</i>
Anteby S.O., <i>Jerusalem (Israel)</i>	Gerbaulet A., <i>Villejuif (France)</i>	Monsonogo J., <i>Paris (France)</i>
Audet-Lapointe P., <i>Montreal (Canada)</i>	Gorins A., <i>Paris (France)</i>	Pinotti A., <i>São Paulo (Brazil)</i>
Ayhan A., <i>Ankara (Turkey)</i>	Heintz A.P.M., <i>Utrecht (The Netherlands)</i>	Piura B., <i>Beer Sheva (Israel)</i>
Balat O., <i>Graziantep (Turkey)</i>	Ioannidou-Mouzaka L., <i>Athens (Greece)</i>	Piver S.M., <i>Buffalo, NY (USA)</i>
Barber H.K., <i>New York, NY (USA)</i>	Jordan J.A., <i>Birmingham, England (UK)</i>	Rakar S., <i>Ljubljana (Slovenia)</i>
Basta A., <i>Krakow (Poland)</i>	Karseladze A.I., <i>Moscow (Russia)</i>	Raju K.S., <i>London, England (UK)</i>
Bender H.C., <i>Dusseldorf (Germany)</i>	Klastersky J., <i>Bruxelles (Belgium)</i>	Shepherd J.H., <i>London, England (UK)</i>
Benedetti Panici P.L., <i>Rome (Italy)</i>	Kubista E., <i>Vienna (Austria)</i>	Stelmachów J., <i>Warsaw (Poland)</i>
Charkviani T., <i>Tbilisi (Georgia)</i>	Kudelka A.P., <i>Houston, TX (USA)</i>	Tjalma W., <i>Antwerpen (Belgium)</i>
De Oliveira C.F., <i>Coimbra (Portugal)</i>	Maggino T., <i>Padua (Italy)</i>	Ungár L., <i>Budapest (Hungary)</i>
Dexeus S. Jr., <i>Barcelona (Spain)</i>	Markowska J., <i>Poznan (Poland)</i>	Vermorken J.B., <i>Edegem (Belgium)</i>
Di Paola G.R., <i>Buenos Aires (Argentina)</i>	Marth C., <i>Innsbruck (Austria)</i>	Vîrtej P., <i>Bucharest (Romania)</i>
Di Re F., <i>Milan (Italy)</i>	Massuger Leon F.A.G., <i>Nijmegen (The Netherlands)</i>	Wang P.-H., <i>Taipei (Taiwan)</i>
Di Saia P., <i>Orange, CA (USA)</i>		Winter R., <i>Graz (Austria)</i>
Fuller A.F. Jr., <i>Boston, MA (USA)</i>		Yokoyama Y., <i>Hirosaki (Japan)</i>

*Publishing Organization (M. Morsani):*

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)  
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroun-online.com - www.irog.net

*Editorial Office (M. Critelli):*

Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

# European Journal of Gynaecological Oncology

www.irog.net

## General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

### AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

**ANNOUNCEMENTS** regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

**BOOK SAMPLES** for review should be sent to the Editorial offices in Montréal or in Padova.

**COPYRIGHT:** the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

**ADVERTISING INFORMATION:** advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H3, Tél. 514.4893242-4893640, Fax 514.4854513, E-mail: canlux@mggroup-online.com - www.irog.net

**RESPONSIBILITY:** although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faulty or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

### SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

**Subscriptions are entered with prepayment only.** The annual subscription is \$390 US for Institutions, \$200 US for Individuals. For airmail add \$30, for receipt add \$10 US. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.** No bank transfers.

**Claims** for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

# European Journal of Gynaecological Oncology

www.irog.net

## Instructions to Authors

### SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storzione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

**Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publication cannot be returned.**

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

### MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three **manuscripts** typed and double spaced should be submitted by mail (not by email) **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0**. Manuscripts without an electronic disk will not be accepted. **A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere.** Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the **Corresponding Author**, responsible for revision and approval of the proofs, should be indicated. **Full-length articles should not exceed 8 printed pages including tables and references.**

After the **title page** (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: **Summary** (purpose of investigation, methods, results, conclusion - about 150 words), **Key words**, **Content** (a 20-word summary), **Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement** (if any), **References, Tables, Legends**.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

**Authors** must give their complete professional identifications and affiliations, including all academic titles and positions.

**Letters to the editor** should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

**Figures:** Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

**Legends** should be typed on a separate page with Arabic numerals corresponding to the illustrations.

**Tables** should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

**References should be numbered consecutively in the order in which they are first mentioned in the text.** Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

**Articles in Journals:** Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

**Books:** Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

**Acknowledgments** will be limited to appropriate professionals who were contributors to the paper.

**PROOFS** revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved**. Only essential corrections should be made; extensive changes will be charged to the authors.

### BUSINESS MATTERS

The Journal has no commercial advertisements.

**Authors will be expected to contribute to the printing expenses, tables, figures and postage.** For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.** No bank transfers.

**Reprints** should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

**DISTINGUISHED EXPERT SERIES**

- Colposcopy used in a primary setting (routine colposcopy): advantages and concerns** 5  
 P. Bósze - *Budapest, HUNGARY*  
 Colposcopy allows advanced cases of cervical cancer to be reduced because tissue changes can be recognized early on.

**REVIEW ARTICLE**

- Neoadjuvant chemotherapy in gynecological cancers** 11  
 A. Ayhan, H. Celik, P. Dursun, M.C. Salman, K. Yuce - *Ankara, TURKEY*  
 Neoadjuvant chemotherapy in gynecological cancers is an approach that is shown to have positive effects on survival. It increases the rate of resectability in ovarian and cervical cancers and thus contributes to survival.

**ORIGINAL ARTICLES**

- Primary fallopian tube carcinoma: a retrospective clinicopathologic study** 16  
 P. Singhal, K. Odunsi, K. Rodabaugh, D. Driscoll, S. Lele - *Buffalo, NY (USA)*  
 This study evaluated the clinical characteristics and management of rare fallopian tube malignancies that were diagnosed and treated.
- Physicians' attitudes, beliefs and knowledge concerning ovarian cancer** 19  
 L. Elit, K. Trim, J. Sussman - *Ontario, CANADA*  
 Addressing physicians' knowledge, beliefs and attitudes on surgical care of women with ovarian cancer.
- Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma** 25  
 T. Giannopoulos, S. Butler-Manuel, A. Taylor, N. Ngeh, H. Thomas - *Guildford, U.K.*  
 Interval debulking for advanced ovarian cancer may be associated with less morbidity and shorter hospital stay compared to primary surgery.
- Intraplental choriocarcinoma metastasizing to the maternal lung** 29  
 D. Landau, E. Maor, E. Maymon, A. Rabinovich, B. Piura - *Beer-Sheva, ISRAEL*  
 A case of intraplental choriocarcinoma metastasizing to the maternal lung is described and the pertinent literature reviewed.
- Medroxyprogesterone acetate stimulates cdk inhibitors, p21 and p27, in endometrial carcinoma cells transfected with progesterone receptor-B cDNA** 33  
 M. Kawaguchi, J. Watanabe, M. Hamano, Y. Kamata, T. Arai, Y. Nishimura, A. Obokata, T. Jobo, H. Kuramoto - *Kanagawa, JAPAN*  
 p21 and p27 stimulated by MPA are involved in progestin-induced growth suppression of human endometrioid adenocarcinoma.
- Correlation of mammographic appearance and molecular prognostic factors in high-grade breast carcinomas** 39  
 E. Likaki-Karatza, P. Ravazoula, G. Androutopoulos, G. Michail, A. Batistatou, E. Tzorakoleftherakis, H. Kalofonos, G. Kourounis - *Patra, GREECE*  
 The correlation of mammographic appearance and molecular prognostic factors in high-grade breast carcinomas was investigated.
- Loss to follow-up of cervical smears without endocervical columnar cells is not disturbing** 42  
 M.A.J.B. Tacken, J.C.C. Braspenning, J. Mulder, R.P.M.G. Hermens, W.L.D.M. Nelen, D.H. de Bakker, R.P.T.M. Grol - *Utrecht, THE NETHERLANDS*  
 Repeating mass screening Pap smears without endocervical columnar cells has a low follow-up rate and also lacks evidence-based necessity.
- Optimal dose for Stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose** 47  
 Y. Niibe, K. Hayakawa, T. Kanai, S. Tsunoda, M. Arai, T. Jobo, H. Kuramoto, N. Unno - *Kanagawa, JAPAN*  
 Prognosis of uterine cervical adenocarcinoma in locally advanced stage treated with radiation therapy has been considered to be much worse than that of squamous cell carcinoma because the optimal dose for the former one has not been determined.

**Clinical significance of a negative loop electrosurgical excision procedure, conization and hysterectomy for cervical intraepithelial neoplasia** 50

E.F.C. Murta, A.O. Silva, E.A.C. Silva - *Uberaba, MG, BRAZIL*

Frequency of recurrence after negative conization, LEEP and hysterectomy is considerable. Patients with negative specimens should be carefully followed.

**c-kit overexpression in neuroendocrine small cell carcinoma of the uterine cervix** 53

M. Ohwada, T. Wada, Y. Saga, S. Tsunoda, T. Jobo, H. Kuramoto, R. Konno, M. Suzuki - *Saitama, JAPAN*

c-kit overexpression was highly observed in small cell carcinoma of the cervix, therefore molecular targeted therapy may be effective.

**Secondary tumors of the intestines in females: A retrospective clinicopathologic study of seven cases** 56

A. Kondi-Pafiti, D. Grapsa, D. Hasiakos, V. Smyrniotis - *Athens, GREECE*

Secondary tumors of the small and large bowel in females were investigated.

**An analysis of alternative funding for physicians practicing gynecologic oncology in Ontario, Canada prior to 2001** 61

L. Elit - *Hamilton, CANADA*

The policy issue of physician reimbursement was considered by examining the events that preceded the Ontario Gynecologic Oncologists moving from a free-for-service environment to an alternate payment plan in 2001.

**The level of antibody against E6 HPV 16 oncoprotein in blood serum of women with chronic HPV 16 infection and cervical cancer** 65

W. Kędzia, A. Olejnik, M. Schmidt, R. Nawrot, A. Goździcka-Józefiak, H. Kędzia, M. Spaczyński - *Poznań, POLAND*

The aim of this study was to estimate the role of chronic HPV 16 infection and the presence of anti E6 HPV 16 in the initiation of the cancerogenesis process of cervical cancer. The results achieved suggest that chronic infection with HPV 16 and seropositivity for viral antigens are factors favoring a cancerogenic process.

**Immunohistochemical detection of HPV proteins and c-erbB receptors in cervical lesion specimens from young women** 69

P. Ravazoula, G. Androutopoulos, D. Koumoundourou, G. Michail, G. Kourounis - *Patra, GREECE*

Immunohistochemical detection of HPV proteins and c-erbB receptors was carried out on in cervical lesion specimens from young women.

**Mesenchymal tumors of the uterine corpus with heterologous and hematopoietic components: A study of ten cases and review of the literature** 73

A. Kondi-Pafiti, D. Grapsa, E. Kairi-Vassilatou, K. Kontogianni-Katsarou, C. Koliopoulos, D. Botsis - *Athens, GREECE*

Ten cases of mesenchymal tumors of the uterine corpus, massively infiltrated by hematopoietic cells or composed of other benign heterologous elements (adipose tissue in the present cases) were retrieved from the archival files of our laboratory and studied histopathologically. Immunohistochemistry was applied in selected cases.

**Comparison of lornoxicam with tramadol in patient-controlled analgesia after gynecological surgery** 78

M. Karaca, H. Kocoglu, A. Gocmen - *Gaziantep, TURKEY*

The effects of lornoxicam and tramadol were compared in patient-controlled analgesia after gynecological surgery. Both drugs were effective but tramadol had better analgesic efficacy during the first 12 hours.

**The use of complementary and alternative medicine (CAM) therapies by Turkish women with gynecological cancer** 81

Y. Yildirim, S. Tinar, S. Yorgun, E. Toz, B. Kaya, S. Sonmez, D. Balsak - *Izmir, TURKEY*

This study evaluated the characteristics of complementary and alternative medicine usage among 156 Turkish women with gynecological cancer using face-to-face interviews.

**CASE REPORTS**

**Sertoli cell tumor: a rare case in an elderly patient** 86

M.O. Nicoletto, E. Caltarossa, M. Donach, G.B. Nardelli, A. Parenti, A. Ambrosini - *Padova, ITALY*

A rare case of postmenopausal Sertoli-Leydig cell tumor is described.

**Halving of body weight: a case of an ovarian mucinous cystadenoma** 88

M.F. Aslam, N.A. Bedford, M.C.J. Sissons, A.R. Sooltan, S.J. Duthie - *Blackpool, UK*

An interesting case of an ovarian mucinous cystadenoma weighing 40 kg is presented.

**Letter to editor** . . . . . 104

<b>Choriocarcinoma complicated by a vaginal fistula, sepsis and hemorrhagic shock. Case report</b>	90
E.F.C. Murta, R.S. Nomelini, A.M.O. Rua, S.J. Adad - <i>Uberaba, MG, BRAZIL</i>	
Despite the risk of hemorrhage, abscess drainage of metastatic choriocarcinoma may be considered before chemotherapy to prevent sepsis.	
<b>Endometrial carcinosarcoma with osteoclast-like giant cells</b>	92
F. Amant, I. Vandenput, T. Van Gorp, I. Vergote, Ph. Moerman - <i>Leuven, BELGIUM</i>	
Osteoclast-like giant cells have been described in endometrial adenosquamous carcinoma and uterine leiomyosarcoma.	
<b>Bone metastasis as a presenting feature of endometrial adenocarcinoma: case report and literature review</b>	95
C.K. Giannakopoulos, G.K. Kyriakidou, G.E. Toufexi - <i>Athens, GREECE</i>	
The case of a 68-year-old woman, gravida 3, para 3, who presented in 2001 with right hip pain which had started three to four months earlier is presented. X-rays of the right hip revealed a lytic lesion of the pelvic bone.	
<b>Placental site trophoblastic tumor: A case report</b>	98
K. Jeremic, M. Gojnic, V. Milenkovic, V. Boskovic, M. Berisavac, N. Zečević - <i>Belgrade, SERBIA AND MONTENEGRO</i>	
The case of a 30-year-old patient, nulliparous and with one miscarriage who was admitted to the Institute of Gynecology and Obstetrics, Clinical Center of Serbia, with a diagnosis of uterine myoma and adnexal mass is presented.	
<b>Gastrointestinal stromal tumors presenting as pelvic masses: Report of two cases</b>	101
S. Erkanli, F. Kayaselcuk, N. Törer, F. Bolat, E. Tarim, E. Simsek, E. Kuscu - <i>Adana, TURKEY</i>	
GISTs should be strongly considered in the differential diagnosis of ovarian tumors.	
<b>Letter to editor . . . . .</b>	104

---

## ERRATA - CORRIGE

**Uterine pathologies in patients undergoing tamoxifen therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings** - M. Le Donne, M. Lentini<sup>1</sup>, L. De Meo<sup>2</sup>, V. Benedetto, M. Misi<sup>3</sup> - *Messina, ITALY*  
*Department of Gynecological, Obstetric Sciences and Reproductive Medicine, <sup>1</sup>Department of Human Pathology, <sup>2</sup>Department of Financial, Social and Environment Economics, <sup>3</sup>Oncological Surgery Unit, University of Messina (Italy)*

Vol. XXVI, n. 6, 2005, pag. 623

**Errata:** M. Le Donne, M. Lentini<sup>1</sup>, L. De Meo<sup>2</sup>, V. Benedetto, M. Misi<sup>3</sup>

**Corrige:** M. Le Donne, M. Lentini<sup>1</sup>, L. De Meo<sup>2</sup>, V. Benedetto, M. Misi<sup>3</sup>

---

## EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY

Vol. XXVII, Number 1, 2006

ISSN: 0392-2936

I.R.O.G. CANADA, Inc.

Publisher office: 4900 Côte St. Luc - Apt. 212 - Montréal, Québec H3W 2H3 (Canada) - Tél.: (514) 4893640-4893242 - Fax: (514) 4854513

E-mail: canlux@mgroup-online.com - www.irog.net

ALL RIGHTS RESERVED

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopies, recordings, nor any information storage and retrieval system without written permission from the copyright owner.

Printed in Italy